Immune-checkpoint inhibitors (ICIs) have shown remarkable efficacy in multiple cancer types [1]. However, these therapies may lead to immune-related adverse events (irAEs) as they promote immune stimulation or interfere with immune tolerance [2]. irAEs include both systemic and organ-specific toxicities (mostly, hypophysitis, colitis, hepatitis, and pneumonitis). Vasculitis, although representing a rare irAE, is one of the most intriguing one as its presentation can be extremely heterogeneous [3, 4] and can be easily misdiagnosed.
